Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

Garassino MC, Ahn MJ, Schick M, Kapil A, Paz-Ares L, Lisberg A, Johnson ML, Pérol M, Shimizu T, Heist R, Spira A, Okamoto I, Girard N, Cornelissen R, Pons-Tostivint E, Hong MH, Zwirtes R, Chiaverelli R, Rebelatto M, Sung M, Deng C, Harper J, Carroll D, Sade H, Sands J. Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer. Nat Med. 2026 Nov 11. doi: 10.1038/s41591-026-04716-9. Epub ahead of print. PMID: 43015400.


Related Posts